Results 31 to 40 of about 36,269 (231)

Activating somatic FGFR2 mutations in breast cancer. [PDF]

PLoS ONE, 2013
It is known that FGFR2 gene variations confer a risk for breast cancer. FGFR2 and FGF10, the main ligand of FGFR2, are both overexpressed in 5-10% of breast tumors.
Nadine Reintjes, Yun Li, Alexandra Becker, Edyta Rohmann, Rita Schmutzler, Bernd Wollnik   +5 more
doaj   +1 more source

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Nature, 2022
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1.
D. Zingg, J. Bhin, Julia Yemelyanenko, S. Kas, F. Rolfs, C. Lutz, Jessica K. Lee, S. Klarenbeek, Ian M. Silverman, S. Annunziato, Chang S. Chan, S. Piersma, Timo Eijkman, Madelon Badoux, E. Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, R. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, L. Henneman, M. V. van Miltenburg, Natalie Proost, Huiling Zhen, E. Wientjens, Roebi de Bruijn, J. D. de Ruiter, U. Boon, Renske de Korte-Grimmerink, Bas van Gerwen, L. Féliz, G. Abou-Alfa, J. Ross, M. van de Ven, Sven Rottenberg, Edwin Cuppen, A. V. Chessex, Siraj M. Ali, Timothy C. Burn, Connie R Jimenez, Shridar Ganesan, L. Wessels, Jos Jonkers   +47 more
semanticscholar   +1 more source

Neonatal loss of FGFR2 in astroglial cells affects locomotion, sociability, working memory, and glia-neuron interactions in mice

Translational Psychiatry, 2023
Fibroblast growth factor receptor 2 (FGFR2) is almost exclusively expressed in glial cells in postnatal mouse brain, but its impact in glia for brain behavioral functioning is poorly understood.
Hanna E. Stevens, Soraya Scuderi, Sarah C. Collica, Simone Tomasi, Tamas L. Horvath, Flora M. Vaccarino   +5 more
doaj   +1 more source

Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway

Cells, 2019
Tight regulation of signaling from receptor tyrosine kinases is required for normal cellular functions and uncontrolled signaling can lead to cancer. Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that induces proliferation and
Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Antoni Wiedlocha, Ellen Margrethe Haugsten   +4 more
doaj   +1 more source

Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux. [PDF]

PLoS ONE, 2013
Pax3cre-mediated deletion of fibroblast growth factor receptor 2 (Fgfr2) broadly in renal and urinary tract mesenchyme led to ureteric bud (UB) induction defects and vesicoureteral reflux (VUR), although the mechanisms were unclear. Here, we investigated
Kenneth A Walker, Sunder Sims-Lucas, Valeria E Di Giovanni, Caitlin Schaefer, Whitney M Sunseri, Tatiana Novitskaya, Mark P de Caestecker, Feng Chen, Carlton M Bates   +8 more
doaj   +1 more source

Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene

Cells, 2023
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but
Garima Dixit, Benjamin A. Pappas, Gourav Bhardwaj, Willow Schanz, Thorsten Maretzky   +4 more
doaj   +1 more source

FGFR2 amplification in colorectal adenocarcinoma [PDF]

Molecular Case Studies, 2017
FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell ...
Carter, Jamal H, Cottrell, Catherine E, McNulty, Samantha N, Vigh-Conrad, Katinka A, Lamp, Stephen, Heusel, Jonathan W, Duncavage, Eric J   +6 more
openaire   +3 more sources

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma

Cancer Treatment and Research Communications, 2022
According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma.
Chunye Huang, Qin Wen, Jingyi Chen, Hongguang Zhong, Xiaojun Xiang, Jianping Xiong, Jun Deng   +6 more
openaire   +3 more sources

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma.

Cancer Discovery, 2021
We conducted next generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree.
J. Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, H. Gupta, D. Rubinson, Isobel J. Fetter, J. Hornick, J. Nowak, G. Siravegna, L. Goyal, Lei Shi, L. Brais, M. Loftus, A. Shinagare, T. Abrams, T. Clancy, Jiping Wang, Anuj K. Patel, F. Brichory, Anne Vaslin Chessex, R. Sullivan, Rachel B. Keller, Sarah L. Denning, E. Hill, G. Shapiro, Anna Pokorska-Bocci, C. Zanna, K. Ng, D. Schrag, P. Janne, W. Hahn, A. Cherniack, R. Corcoran, M. Meyerson, Antoine Daina, V. Zoete, N. Bardeesy, B. Wolpin   +39 more
semanticscholar   +1 more source

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib.

Cancer Discovery, 2020
Pemigatinib, a selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase 2 study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory ...
I. Silverman, A. Hollebecque, L. Friboulet, S. Owens, R. Newton, H. Zhen, L. Féliz, C. Zecchetto, D. Melisi, T. Burn   +9 more
semanticscholar   +1 more source